CVRx, Inc.
CVRXHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United. The company carries a $37.8M market cap, placing it firmly in the micro-cap category. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.
Market Cap
$37.8M
Beta
0.77
P/E (TTM)
—
P/E (Fwd)
-0.76
EPS (TTM)
$-1.97
EPS (Fwd)
$-1.88
ROE
-133.4%
ROA
-28.7%
Cash
$64.6M
Total Debt
$59.4M
Free CF
-$23.8M
52W Change
-86.3%
Annual Financials
Cash vs Debt
Where CVRX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CVRX finished 73.43% below its 150-day moving average ($5.08) and 75.72% below its 200-day moving average ($5.56). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CVRX overbought or oversold?
At the October 20, 2026 close, CVRX's RSI(14) was 14.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
CVRx, Inc. holds $64.6M in cash against $59.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$23.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -133.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $22.5M (2022) to $56.7M (2025), reflecting a 152% increase over the period.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CVRX.